Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 99.18 USD -0.68% Market Closed
Market Cap: 250.9B USD
Have any thoughts about
Merck & Co Inc?
Write Note
Section:
 

Relative Value

The Relative Value of one MRK stock under the Base Case scenario is 135.32 USD. Compared to the current market price of 99.18 USD, Merck & Co Inc is Undervalued by 27%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MRK Relative Value
Base Case
135.32 USD
Undervaluation 27%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4
P/S
P/S
Price to Sales
4
vs History
84
vs Industry
25
Median 3Y
4.6
Median 5Y
4.4
Industry
2.5
Forward
3.9
More Details
20.7
P/E
P/E
Price to Earnings
20.7
vs History
49
vs Industry
2
Median 3Y
21.6
Median 5Y
20.8
Industry
21.9
Forward
12.7
More Details
13.7
P/OCF
P/OCF
Price to OCF
13.7
vs History
71
vs Industry
20
Median 3Y
15.2
Median 5Y
15.1
Industry
16.5
More Details
15.1
P/FCFE
P/FCFE
Price to FCFE
15.1
vs History
84
vs Industry
20
Median 3Y
18.8
Median 5Y
18
Industry
23.6
More Details
5.6
P/B
P/B
Price to Book Value
5.6
vs History
73
vs Industry
8
Median 3Y
6
Median 5Y
6.3
Industry
2.1
More Details
4.3
EV/S
EV/S
Enterprise Value to Sales
4.3
vs History
84
vs Industry
22
Median 3Y
4.9
Median 5Y
4.8
Industry
2.6
Forward
4.2
More Details
5.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
5.6
vs History
96
vs Industry
28
Median 3Y
6.6
Median 5Y
6.6
Industry
5.2
More Details
10.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
10.5
vs History
90
vs Industry
9
Median 3Y
11.8
Median 5Y
12.7
Industry
13.3
Forward
10.2
More Details
12.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
12.5
vs History
90
vs Industry
7
Median 3Y
14.3
Median 5Y
15.4
Industry
16.6
Forward
10.9
More Details
14.9
EV/OCF
EV/OCF
Enterprise Value to OCF
14.9
vs History
65
vs Industry
20
Median 3Y
16.6
Median 5Y
16.5
Industry
15.6
More Details
18.3
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.3
vs History
87
vs Industry
14
Median 3Y
21.8
Median 5Y
22.8
Industry
19.1
More Details
2.7
EV/IC
EV/IC
Enterprise Value to IC
2.7
vs History
47
vs Industry
23
Median 3Y
3.1
Median 5Y
2.7
Industry
1.9
More Details

Multiples Across Competitors

MRK Competitors Multiples
Merck & Co Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
US
Pfizer Inc
NYSE:PFE
145.4B USD 2.4 34.2 10.3 15.5
P/E Multiple
Earnings Growth
US
Merck & Co Inc
NYSE:MRK
Average P/E: 32.6
20.7
7 321%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A
US
Pfizer Inc
NYSE:PFE
34.2
733%

See Also

Summary
MRK intrinsic value, competitors valuation, and company profile.
DCF Valuation
MRK stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MRK stock valuation using valuation multiples.
Wall Street Estimates
MRK price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MRK stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 201,200+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.